The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RCKT | -77.64% | -86.3% | -32.78% | -69% |
| S&P | +16.9% | +95.99% | +14.39% | +148% |
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
Its near-term risks are subtle but bigger than their flying stock price might indicate.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$2.54M | -8.6% |
| Market Cap | $263.96M | -86.5% |
| Market Cap / Employee | $0.88M | 0.0% |
| Employees | 299 | 11.6% |
| Net Income | -$68.92M | 1.0% |
| EBITDA | -$65.14M | 8.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $32.82M | -15.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $22.31M | -2.8% |
| Short Term Debt | $2.89M | 1.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -59.33% | -3.6% |
| Return On Invested Capital | -41.02% | -6.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$49.03M | 12.1% |
| Operating Free Cash Flow | -$48.98M | 9.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.37 | 3.47 | 1.53 | 0.63 | -85.64% |
| Price to Tangible Book Value | 5.24 | 4.31 | 1.78 | 0.75 | -85.47% |
| Enterprise Value to EBITDA | -22.81 | -14.57 | -7.19 | -0.39 | -98.40% |
| Return on Equity | -59.3% | -54.1% | -60.5% | -69.6% | 8.30% |
| Total Debt | $25.64M | $25.50M | $25.35M | $25.20M | -2.31% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
